Furthermore, combined inhibition of DNMT1 together with G9a HMT, which is associated with histone modification, synergistically inhibits the growth of HCC, suggesting that combined DNMT1/G9a targeting is a promising strategy in the treatment of HCC. This evidence concerns the gene DNMT1 and hepatocellular carcinoma.